References
- Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine27(Suppl. 2), B42–B50 (2009).
- Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
- Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine27(Suppl. 2), B112–B116 (2009).
- Borrow R, Carlone GM, Rosenstein N et al.Neisseria meningitidis group B correlates of protection and assay standardization – international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine24(24), 5093–5107 (2006).
- Caugant DA, Maiden MC. Meningococcal carriage and disease – population biology and evolution. Vaccine27(Suppl. 2), B64–B70 (2009).
- Maiden MCJ, Caugant DA. The population biology of Neisseria meningitidis: implications for meningococcal disease, epidemiology and control. In: Handbook of Meningococcal Disease. Frosch M, Maiden MCJ (Eds). Wiley-VCH, Weinheim, Germany, 17–35 (2006).
- Moxon ER, Rainey PB, Nowak MA, Lenski RE. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr. Biol.4(1), 24–33 (1994).
- Saunders NJ, Jeffries AC, Peden JF et al. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol. Microbiol.37(1), 207–215 (2000).
- Grifantini R, Bartolini E, Muzzi A et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol.20(9), 914–921 (2002).
- Grifantini R, Sebastian S, Frigimelica E et al. Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc. Natl Acad. Sci. USA100(16), 9542–9547 (2003).
- Findlow J, Holland A, Andrews N et al. Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay. Clin. Vaccine Immunol.14(11), 1451–1457 (2007).
- Borrow R, Aaberge IS, Santos GF et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12(8), 970–976 (2005).
- Madico G, Welsch JA, Lewis LA et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol.177(1), 501–510 (2006).
- Schneider MC, Exley RM, Chan H et al. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol.176(12), 7566–7575 (2006).
- Murphy E, Andrew L, Lee KL et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis.200(3), 379–389 (2009).
- Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine18(23), 2476–2481 (2000).